Literature DB >> 23505997

Power and pulsed Doppler evaluation of prostatic artery blood flow in normal and benign prostatic hyperplasia-affected dogs.

R Zelli1, R Orlandi, A Troisi, L Cardinali, A Polisca.   

Abstract

This study was carried out with the objectives to test the differences in the haemodynamic characteristics of the prostatic artery in normal and benign prostatic hyperplasia (BPH)-affected dogs using Doppler ultrasonography. In sixteen male German shepherd dogs, prostatic volume was detected and prostatic biopsy was performed. The prostatic artery blood flow parameters determined were as follows: peak systolic velocity (PSV), end diastolic velocity (EDV), Resistive Index (RI) and Pulsatility Index. The power Doppler mode was used for colour flow mapping of the prostatic artery. In PW mode at marginal locations, the waveforms recorded showed a continuous pattern typical of the high-resistance vessels, while in subcapsular locations, the waveforms recorded were continuous characteristic of the low-resistance vessel. Peak systolic velocity and EDV in both locations were significantly higher in BPH group (p < 0.001) than normal group (p < 0.05). Pixel number in BPH group in both locations was significantly higher (p < 0.05) compared to the normal group. This study shows that Doppler ultrasonography represents a valid and non-invasive method for the characterization of the blood flow in the prostatic artery in dogs affected with BPH. Moreover, statistically significant differences of blood flow velocities in prostatic artery in normal and BPH-affected dogs were detected. The RI was not able to differentiate normal dogs from dogs affected by BPH and therefore is not a parameter usable for diagnostic purposes, while Power Doppler could represent an additional diagnostic tool.
© 2013 Blackwell Verlag GmbH.

Entities:  

Mesh:

Year:  2013        PMID: 23505997     DOI: 10.1111/rda.12159

Source DB:  PubMed          Journal:  Reprod Domest Anim        ISSN: 0936-6768            Impact factor:   2.005


  7 in total

1.  Does finasteride treatment for benign prostatic hyperplasia influence sperm DNA integrity in dogs?

Authors:  Daniel S R Angrimani; Luana C Bicudo; Nuria Llamas Luceño; Bruno R Rui; Matheus F Silva; João D A Losano; Bart Leemans; Ann Van Soom; Camila I Vannucchi
Journal:  Basic Clin Androl       Date:  2020-07-16

2.  Use of platelet-rich plasma for the treatment of prostatic cysts in dogs.

Authors:  Enrico Bigliardi; Anna Maria Cantoni; Valeria De Cesaris; Laura Denti; Virna Conti; Mara Bertocchi; Francesco Di Ianni; Enrico Parmigiani; Stefano Grolli
Journal:  Can J Vet Res       Date:  2018-10       Impact factor: 1.310

3.  Prostatic hyperplasia: Vascularization, hemodynamic and hormonal analysis of dogs treated with finasteride or orchiectomy.

Authors:  Daniel S R Angrimani; Maria Claudia P Francischini; Maíra M Brito; Camila I Vannucchi
Journal:  PLoS One       Date:  2020-06-25       Impact factor: 3.240

4.  Reproductive and endocrinological effects of Benign Prostatic Hyperplasia and finasteride therapy in dogs.

Authors:  Daniel S R Angrimani; Maíra M Brito; Bruno R Rui; Marcílio Nichi; Camila I Vannucchi
Journal:  Sci Rep       Date:  2020-09-09       Impact factor: 4.379

5.  Correlation of Prostatic Artery Blood Flow Assessed by Doppler Ultrasonography with Semen Characteristics in Beagle Dogs.

Authors:  Victoria Luño; Marina Servián; Felisa Martínez; María Borobia; Noelia González; Lydia Gil
Journal:  Animals (Basel)       Date:  2020-11-09       Impact factor: 2.752

Review 6.  Highlights on the Canine Prostatic Specific Esterase (CPSE): A diagnostic and screening tool in veterinary andrology.

Authors:  Monica Melandri; Salvatore Alonge
Journal:  Vet Med Sci       Date:  2020-09-02

7.  Characterization of Testicular Tumor Lesions in Dogs by Different Ultrasound Techniques.

Authors:  Riccardo Orlandi; Emanuela Vallesi; Cristiano Boiti; Angela Polisca; Paolo Bargellini; Alessandro Troisi
Journal:  Animals (Basel)       Date:  2022-01-17       Impact factor: 2.752

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.